GBT is a clinical-stage biopharmaceutical company that focuses on discovering, developing, and delivering innovative treatments that provide hope to underserved patient communities. GBT is developing its product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. It was founded in 2012 and is headquartered in San Francisco, California.

Shanghai Super High Environmental Protection Technology Co., Ltd., established on 1998-02-26, Business scope includes general items:Manufacture of special equipment for environmental protection;Sales of special instruments and meters for environmental monitoring;Special Equipment Repair;Manufacturing of special instruments and meters for environmental monitoring;Environmental protection special equipment sales;Environmental Consulting Services;Resource recycling technology research and development;Industrial Engineering Design Services;Mechanical equipment research and development;Machinery sales;General machinery and equipment installation services;Manufacture of special machinery and equipment for water resources;Mechanical and electrical equipment manufacturing;Sales of mechanical and electrical equipment;Resource recycling service technical consultation;Engineering and Technology Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Engineering Management Services;Manufacture of dust removal technology and equipment;Intelligent power transmission and distribution and control equipment sales;electronic(gas)Manufacturing of physical equipment and other electronic equipment;Energy saving management service;General parts manufacturing;General equipment manufacturing(Does not include special equipment manufacturing);Machinery and Equipment Leasing;Carbon emissions,carbon conversion,carbon capture,Research and development of carbon sequestration technology;Manufacturing of engineering plastics and synthetic resins;Sales of engineering plastics and synthetic resins;Synthetic Materials Sales;synthetic material manufacturing(Free of Hazardous Chemicals);New material technology research and development;New material technology promotion service;Manufacturing of rubber products;Rubber Products Sales;Seal Manufacturing;Seal Sales;Manufacturing of sealing packing;Sealing packing sales;Sealant manufacturing;Sales of high-performance fibers and composite materials;High-performance fiber and composite material manufacturing;Manufacturing of plastic products;Sales of plastic products;electronic,Mechanical equipment maintenance(No special equipment);total mass4.5Road freight transport of ordinary freight vehicles of 1 ton or less(Except network freight and dangerous goods).(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Dongguan Pengzhi Biotechnology Co., Ltd., established on 2016-08-22, Business scope includes biological products,R&D of medical devices,Production,Sales and technology transfer,Technical Services;Sales:Chemical Products(Free of Hazardous Chemicals);Import and export,Technology Import and Export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Labsystems Oy, a subsidiary of Thermo Fisher Scientific, Inc., is a Finnish company focused on electronic computers. The firm was founded by Osmo Antero Suovaniemi. Life Sciences International Plc acquired Labsystems Oy on May 01, 1993 for $51.77 million.

Eiken Chemical Co., Ltd. engages in the manufacture and sale of clinical diagnostics products and equipment. It operates through following business divisions: Clinical Diagnostics and Testing of Food and Environment. The Clinical Diagnostics division handles the manufacture of clinical diagnostic products and services. The Testing of Food and Environment division deals with the sale of reagents for microbiological tests on food for poisoning bacteria, and environment for contamination of work environments. Its products include fecal immunochemical testing equipment, molecular test loop-mediated isothermal amplification (LAMP), immunological and serological reagents, and rapid diagnostic tests such as IMMUNOCATCH Norovirus, IMMUNOCATCH Legionella, and IMMUNOCATCH Streptococcus pneumoniae. The company was founded on February 20, 1939 and is headquartered in Tokyo, Japan.

Operates a biomedical group

Green Cross Corp. engages in the manufacture and sale of pharmaceutical products. Its products include medicines for blood, over the counter drugs, generals, vaccines, and others. The company was founded on November 1, 1969 and is headquartered in Yongin, South Korea.

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

Commonwealth Scientific & Industrial Research Organisation provides scientific and industrial research services. It plays a role in collaboration within the Australian national innovation system and as an advisor to government, industry and the community. The company was founded in 1916 and is headquartered in Canberra, Australia.

Gui'an New District Kangshun Biotechnology Co., Ltd., established on 2017-07-14, Business scope includes legal,regulations,Those prohibited by the State Council's decision shall not operate;law,regulations,The State Council has decided to allow(approval)of,After approval by the examination and approval authority(approval)file management;law,regulations,The State Council has decided that a license is not required(approval)of,Market entities independently choose to operate.(Biotechnology Research,medical technology development,medical technology transfer,Medical Technology Consulting,Medical Technology Services,1-3Class medical machinery(Including research and development of clinical transfer analytical instruments and in vitro diagnostic reagents,production and sales,Engaged in the import and export of goods and technology)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments))

Research Corporation Technologies, Inc. provides investment related services. It operates as technology development company that typically invests in new technology platforms in life sciences, healthcare technology, biomedical, preclinical and clinical-stage therapeutics, devices, drugs, and diagnostics, medical devices, and biotech tools for gene expression and protein production with medical devices. The company was founded in 1987 and is headquartered in Tucson, AZ.

UCLB is the commercialisation company of UCL and its partner NHS Trusts. They bring to market truly world-leading, world-changing technologies, innovations that have a real and positive impact on people’s lives. UCLB the access point to the wealth of innovation and intellectual property emanating from UCL and partner hospitals including University College Hospital, Great Ormond Street Hospital, Royal Free Hospital and Moorfields Eye Hospital. They offer a number of services to assist the technology development process, from consultancy through to collaborative research, IP licensing and the creation of spinout companies and joint ventures to maximise the commercial potential of new discoveries, materials and processes.

Ipeeres Co., Ltd., a subsidiary of SkinFood Co. Ltd., is a South Korean company that manufactures cosmetic products.

Founded in 2008, LifeHealth, LLC is dedicated to the point-of-care diagnostics market by providing products that enable early disease detection to improve human health. Their philosophy is that early detection is the most effective way to improve the quality of human life and to reduce the cost of care.\nThe Company’s first commercial product line is the IRMA TruPoint Blood Analysis System, the world’s first point-of-care product line for measuring blood gases, which LifeHealth acquired in 2014. For over two decades, this system has been at the forefront of providing instant critical lab results to clinicians. The system has delivered quality clinical performance since its inception.\nLifeHealth is developing additional novel proprietary assays to further advance public health. These new developments and improvements promise to change the standard of cardiovascular screening and disease monitoring worldwide.

Hemanext is a medical technology company offering a blood processing, storage, and transfusion solution. Hemanext enhances the effectiveness, safety, affordability, and efficacy of transfusion therapy. Hemanext helps the community of transfusion medicine in its initiatives to save lives and enhance patient outcomes.

Cell ID Pte Ltd. manufactures and sells point-of-care diagnostics devices. It provide solutions for the diagnostics world with patented platform solutions: smart lateral flow, smart micro-fluidic and printed biosensors. The company was founded on March 1, 2013 and is headquartered in Singapore.

Fujikura Kasei Co., Ltd. engages in the manufacture and sale of acrylic resin-derived products. It operates through the following segments: Coating for Plastics, Architectural Coatings, Electronics Materials, Functional Polymers, and Synthetic Resins. The Coating for Plastics segment provides coating materials for plastic products. The Architectural Coatings segment offers architectural coating materials. The Electronics Materials segment produces conductive resin coatings and adhesives. The Functional Polymers segment manufactures adhesive-based resin products. The Synthetic Resins segment deals with acrylic raw materials and acrylic resin-processed products. The company was founded on September 22, 1938 and is headquartered in Tokyo, Japan.

CSL Behring AG, part of CSL Ltd., is a company headquartered in Bern, Switzerland. The firm develops biological products.

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development, manufacturing, and commercialization of important medicines for patients with cancer and other life-threatening conditions. Enzon has a portfolio of four marketed products, ONCASPAR®, DEPOCYT®, ABELCET® and ADAGEN®. The Company's drug development programs utilize several cutting-edge approaches, including its industry-leading PEGylation technology platform used to create product candidates with benefits such as reduced dosing frequency and less toxicity. Enzon's PEGylation technology was used to develop two of its products, ONCASPAR and ADAGEN, and has created a royalty revenue stream from licensing partnerships for other products developed using the technology. Enzon also engages in contract manufacturing for several pharmaceutical companies to broaden the Company's revenue base.